Expected Moves

Expected clinical data readout or regulatory update regarding Evaxion's AI-designed personalized cancer immunotherapies.

Q3 2026 financial results with updated management commentary on clinical expenditures and strategic partnerships.

Fourth-quarter and full-year 2026 earnings, detailing year-end cash position and 2027 strategic outlook.

Anticipated window for a potential strategic collaboration or non-dilutive licensing agreement validating the AI-immunology platform.